Selprazine was developed as a sedative agent for inhibition of aggression. Information about the current use of this compound is not available.

Saterinone, a dual-action drug combines both alpha-1 blocking vasodilatory property and phosphodiesterase III (PDE III) inhibition--mediated inotropism. PDE III inhibitors are well established in the acute intravenous treatment of patients with decompensated chronic congestive heart failure. Saterinone was demonstrated to be a safe and potent drug on short-term application without major changes in myocardial oxygen consumption. Saterinone was studied in phase II trials in Germany for the treatment of heart failure. However, the development of this drug has been discontinued.

Naftypramide is a nonsteroidal anti-inflammatory drug. It was used in the treatment of gynecological inflammatory diseases.

Mitonafide is a nitro-containing antitumor drug. Mitonafide participated in clinical trials phase II in colorectal cancer patients, however, the results have shown that the drug was not active and induced severe myelotoxicity. Besides, the drug was involved in phase II for the patients with non-small cell lung cancer (NSCLC), where it was not active in spite of the safe administration. Information about the current development of this drug is not available.

Metitepine, a psychotropic agent was developed as a non-selective antagonist of serotonin, dopamine, and adrenergic receptors. Metitepine has never been marketed.

Aranotin, a metabolite of Arachniotus aureus, possesses the antiviral and antibiotic properties. It inhibits viral RNA synthesis against strains of rhino-, coxsackie, polio- and parainfluenza viruses.

FLAVAMINE is a diterpenoid alkaloid isolated from the roots of Aconitum fiavum.